June 14, 2004


Mr. Samuel L. Shanaman

5 Millstone Circle

Andover, MA 01810


Dear Sam:


      This letter will serve to confirm and memorialize the agreement reached

between you and the Board of Directors ("Board") of PolyMedica Corporation

("PolyMedica" or the "Company") upon your transition from Interim Chief

Executive Officer to full-time Chief Executive Officer of the Company pursuant

to the vote of the Board on January 12, 2004.


      As Chief Executive Officer of PolyMedica, you will perform such

management, advisory and related services to and for the Company and its

subsidiaries as may be reasonably requested from time to time by the Board. You

shall report directly to the Board or its designees.


      You shall receive an annualized base salary of $500,000 ("Base Salary")

payable in equal installments pursuant to the Company's customary payroll

policies in force at the time of payment (but in no event less frequently than

monthly), less all required and authorized payroll deductions and state and

federal withholdings. Your Base Salary may be adjusted from time to time in the

sole discretion of the Company's Board or the Compensation Committee of the

Board (the "Compensation Committee").


      You will be eligible for all normal Company benefits offered to senior

executives administered in accordance with Company policy, which presently

include, among other benefits, long-term disability, life insurance, dental and

health insurance and Company holidays. Subject to length of service and other

eligibility requirements, you will be entitled to participate in the Company's

401(k) retirement plan and Employee Stock Purchase Plan.


      You will earn vacation at the rate of six (6) weeks annually.


      You also will be eligible, in the sole discretion of the Compensation

Committee, to receive an annual discretionary bonus equal to 100% of your Base

Salary based upon objectives to be mutually agreed upon by you and the

Compensation Committee.


      As set forth more fully in the Option Agreement dated February 23, 2004

previously provided to you, you received an option to purchase 240,000 shares of

the Company's Common Stock with 60,000 of such shares being fully vested upon

issuance and the remaining 180,000 shares vesting quarterly over the next three



      Pursuant to the Company's customary policies in force at the time of

payment, you shall be promptly reimbursed for all reasonable and necessary

business related expenses incurred in connection with, or related to, the

performance of services under this letter agreement.


      You are also being provided contemporaneously with this letter agreement a

Retention Agreement that sets forth certain rights that you will have in the

event a change in control of the company occurs during the term of your

employment with the Company.


      You hereby acknowledge and reaffirm your obligations under the

Confidential Disclosure Agreement dated November 6, 2001 and acknowledge your

obligations under the Non-Competition and Non-Solicitation Agreement and the

Invention and Non-Disclosure Agreement that you are contemporaneously executing

with this letter agreement (the "Additional Agreements"), all of which shall

survive the termination of this letter agreement.



Samuel L. Shanaman

June 14, 2004


      Any dispute or controversy arising out of or relating in any way to your

employment with and/or separation from the Company (including, but not limited

to, all claims, demands or actions under any federal, state or local statute or

regulation regarding employment discrimination, and/or all claims, demands or

actions concerning the interpretation, construction, performance or breach of

this letter agreement) shall be settled by arbitration held in Boston,

Massachusetts in accordance with the Rules of the American Arbitration

Association, before an arbitrator who shall have experience in the area of the

matter in dispute. Each party shall bear its own costs and attorneys' fees in

connection with any arbitration pursuant to this paragraph; provided, however,

that this paragraph shall not apply to any dispute or controversy arising out of

or relating in any way to the interpretation, construction, performance or

breach of the Additional Agreements, and no such dispute or controversy shall be

deemed to be arbitrable in the absence of the Board's written agreement.


      Nothing contained in this letter agreement shall preclude you from

devoting incidental and insubstantial amounts of time to activities other than

the business of the Company and which are not inconsistent with the best

interests of the Company.


      This letter agreement contains the entire understanding between you and

the Board with respect to the subject matter addressed in this letter agreement

and supersedes all prior agreements and understandings between you and the Board

with respect to such subject matter; provided that nothing in this letter

agreement shall affect your obligations under the Additional Agreements.


      This letter agreement may not be amended or supplemented except by written

instrument executed by both you and a duly authorized representative of the

Board. No failure to exercise, and no delay in exercising, any right, power or

privilege hereunder shall operate as a waiver thereof. No waiver of any breach

of any provision of this letter agreement shall be deemed to be a waiver of any

preceding or succeeding breach of the same or any other provision.


      The rights and obligations of this letter agreement shall bind and inure

to the benefit of any successor of the Company by reorganization, merger or

consolidation, or any assignee of all or substantially all of the Company's

business and properties.


      This letter agreement shall continue in effect until terminated by vote of

the Board.




                                      /s/ Marcia J. Hooper


                                      Marcia J. Hooper

                                      Compensation Committee

                                      Board of Directors, PolyMedica Corporation




/s/ Samuel L. Shanaman


Samuel L. Shanaman